Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Liu Xile, Charles Z Ding, Weifeng Mao, Yuxin Qin, Shansong Zheng, Yingying Yang, Qingmei Zheng, Long Zhang and Shuyong Zhao | ||||||||||||
Title | Preclinical evaluation of WX-0593, a potent orally active ALK inhibitor | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/78/13_Supplement/4794.short | ||||||||||||
Abstract Text | Cancer Res 2018;78(13 Suppl):Abstract nr 4794 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Iruplinalkib | Iruplinalkib | 21 | 0 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Iruplinalkib | WX0593|WX 0593|FL 006|FL-006|FL006|WX-0593 | ALK Inhibitor 32 EGFR Inhibitor (Pan) 61 ROS1 Inhibitor 20 | Iruplinalkib (WX-0593) inhibits ALK and ROS1, with additional activity against EGFR mutations, which may lead to decreased tumor growth (PMID: 35087031; Cancer Res 2018;78(13 Suppl):Abstract nr 4794). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|